Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model

被引:12
作者
Yonezawa, Sei
Asai, Tomohiro
Oku, Naoto
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Suruga Ku, Shizuoka 4228526, Japan
[2] Univ Shizuoka, Sch Pharmaceut Sci, COE Program Century 21st, Suruga Ku, Shizuoka 4228526, Japan
关键词
anti-neovascular therapy; liposome; pancreatic cancer; angiogenesis; GROWTH; BEVACIZUMAB; TRIAL;
D O I
10.1016/j.jconrel.2006.12.024
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pancreatic cancer is one of the most serious cancers with poor therapeutic results and prognosis. In here, we proposed a novel treatment strategy of pancreatic cancer by injuring limited angiogenic vessels with liposome containing adriamycin. At first, we established an orthotopic tumor model, which has a hypovascular characteristic of pancreatic tumor. In this model, we obtained the enhanced therapeutic efficacy with liposome that modified by polyethylene glycol (PEG) and a peptide, Ala-Pro-Arg-Pro-Gly (APRPG), having an affinity to neovessels. Histochemical analysis suggested the degradation of angiogenic vessels after treatment with APRPG-PEG-liposomal adriamycin. In addition, we observed colocalization of fluorescence-labeled APRPG-PEG-liposome with angiogenic endothelial cells, although the biodistribution of H-3-labeled liposome did not show the difference in the amount of accumulation between PEG-modified liposome and APRPG-PEG-i-nodified liposome. These results suggested the availability of the anti-neovascular therapy against pancreatic cancer and supply a new sight indication on chemotherapeutics against pancreatic cancer. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 21 条
[1]   Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels [J].
Asai, T ;
Nagatsuka, M ;
Kuromi, K ;
Yamakawa, S ;
Kurohane, K ;
Ogino, K ;
Tanaka, M ;
Taki, T ;
Oku, N .
FEBS LETTERS, 2002, 510 (03) :206-210
[2]   Association of hydrophobically-modified poly(ethylene glycol) with fusogenic liposomes [J].
Auguste, DT ;
Prud'homme, RK ;
Ahl, PL ;
Meers, P ;
Kohn, J .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2003, 1616 (02) :184-195
[3]  
Bruns CJ, 2000, CANCER RES, V60, P2926
[4]   INHIBITION OF THE METASTATIC SPREAD AND GROWTH OF B16-BL6 MURINE MELANOMA BY A SYNTHETIC MATRIX METALLOPROTEINASE INHIBITOR [J].
CHIRIVI, RGS ;
GAROFALO, A ;
CRIMMIN, MJ ;
BAWDEN, LJ ;
STOPPACCIARO, A ;
BROWN, PD ;
GIAVAZZI, R .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (03) :460-464
[5]   Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer [J].
Crane, CH ;
Ellis, LM ;
Abbruzzese, JL ;
Amos, C ;
Xiong, HQ ;
Ho, L ;
Evans, DB ;
Tamm, EP ;
Ng, C ;
Pisters, PWT ;
Charnsangavej, C ;
Delclos, ME ;
O'Reilly, M ;
Lee, JE ;
Wolff, R .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1145-1151
[6]  
Eccles SA, 1996, CANCER RES, V56, P2815
[7]   Biopanning and rapid analysis of selective interactive ligands [J].
Giordano, RJ ;
Cardó-Vila, M ;
Lahdenranta, J ;
Pasqualini, R ;
Arap, W .
NATURE MEDICINE, 2001, 7 (11) :1249-1253
[8]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[9]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[10]   Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer [J].
Kindler, HL ;
Friberg, G ;
Singh, DA ;
Locker, G ;
Nattam, S ;
Kozloff, M ;
Taber, DA ;
Karrison, T ;
Dachman, A ;
Stadler, WM ;
Vokes, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8033-8040